featured
Mutant IDH1 Inhibitor Ivosidenib Combined With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
J. Clin. Oncol 2020 Oct 29;[EPub Ahead of Print], CD DiNardo, AS Stein, EM Stein, AT Fathi, O Frankfurt, AC Schuh, H Döhner, G Martinelli, PA Patel, E Raffoux, P Tan, AM Zeidan, S de Botton, HM Kantarjian, RM Stone, MG Frattini, F Lersch, J Gong, DA Gianolio, V Zhang, A Franovic, B Fan, M Goldwasser, S Daigle, S Choe, B Wu, T Winkler, P VyasFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.